EA199900004A1 - Лекарственный комплекс - Google Patents

Лекарственный комплекс

Info

Publication number
EA199900004A1
EA199900004A1 EA199900004A EA199900004A EA199900004A1 EA 199900004 A1 EA199900004 A1 EA 199900004A1 EA 199900004 A EA199900004 A EA 199900004A EA 199900004 A EA199900004 A EA 199900004A EA 199900004 A1 EA199900004 A1 EA 199900004A1
Authority
EA
Eurasian Patent Office
Prior art keywords
spacer
complex
drug complex
drug
carboxy
Prior art date
Application number
EA199900004A
Other languages
English (en)
Other versions
EA001550B1 (ru
Inventor
Казухиро Иноуе
Хироси Сусаки
Масахиро Икеда
Хироси Куга
Эйдзи Кумазава
Акико Того
Original Assignee
Дайити Фармасьютикал Ко., Лтд.
Драг Деливери Систем Инститьют, Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайити Фармасьютикал Ко., Лтд., Драг Деливери Систем Инститьют, Лтд filed Critical Дайити Фармасьютикал Ко., Лтд.
Publication of EA199900004A1 publication Critical patent/EA199900004A1/ru
Publication of EA001550B1 publication Critical patent/EA001550B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Лекарственный комплекс, в котором остаток лекарственного соединения, такого как противоопухолевое средство, и карбокси(C)алкилдекстрановый полиспирт, полученный путем обработки декстрана в условиях, обеспечивающих практически полное превращение в полиспирт, связаны друг с другом спейсером, состоящим из одной аминокислоты, или спейсером, состоящим из 2-8 аминокислот, связанных пептидной связью. Указанный комплекс отличается великолепной избирательностью к местам локализации опухолей, благодаря чему он оказывает сильное противоопухолевое действие при низкой токсичности.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900004A 1996-06-06 1997-06-05 Лекарственный комплекс EA001550B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14442196 1996-06-06
PCT/JP1997/001914 WO1997046260A1 (en) 1996-06-06 1997-06-05 Drug complexes

Publications (2)

Publication Number Publication Date
EA199900004A1 true EA199900004A1 (ru) 1999-06-24
EA001550B1 EA001550B1 (ru) 2001-04-23

Family

ID=15361795

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900004A EA001550B1 (ru) 1996-06-06 1997-06-05 Лекарственный комплекс

Country Status (17)

Country Link
US (2) US6436912B1 (ru)
EP (1) EP0916348B1 (ru)
JP (1) JP4137183B2 (ru)
KR (1) KR20000016558A (ru)
CN (1) CN1227499A (ru)
AT (1) ATE273715T1 (ru)
AU (1) AU723392B2 (ru)
CA (1) CA2257245A1 (ru)
DE (1) DE69730332T2 (ru)
DK (1) DK0916348T3 (ru)
EA (1) EA001550B1 (ru)
ES (1) ES2229354T3 (ru)
ID (1) ID18298A (ru)
NO (1) NO985666L (ru)
PT (1) PT916348E (ru)
TW (1) TW527183B (ru)
WO (1) WO1997046260A1 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH071238U (ja) * 1993-06-11 1995-01-10 株式会社大井製作所 ドアロック操作用のロッド連結装置
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
EA003398B1 (ru) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
WO2000025825A1 (fr) * 1998-10-30 2000-05-11 Daiichi Pharmaceutical Co., Ltd. Composes dds et procede de dosage de ces composes
MY125378A (en) * 1999-10-15 2006-07-31 Daiichi Sankyo Co Ltd Pentacyclic taxan compound
US6677456B2 (en) 1999-10-15 2004-01-13 Daiichi Pharmaceutical Co., Ltd. Pentacyclic taxan compound
AU2001267831A1 (en) * 2000-06-29 2002-01-08 Daiichi Pharmaceutical Co., Ltd. DDS compound and process for the preparation thereof
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
EP1572242B1 (en) * 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
BR122018071808B8 (pt) * 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
CN103027893B (zh) * 2005-02-18 2014-11-12 国立大学法人德岛大学 含聚氧化烯链的脂质衍生物及含有该衍生物的脂质膜结构体
CN100516067C (zh) * 2006-01-10 2009-07-22 上海恒瑞医药有限公司 具有抗肿瘤活性的紫杉酚衍生物
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
CN107141410B (zh) 2010-05-25 2022-12-09 辛德弗雷克斯公司 聚合物缀合的MetAP2抑制剂及其应用的治疗方法
KR102584005B1 (ko) 2012-10-11 2023-09-27 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
JP6272230B2 (ja) 2012-10-19 2018-01-31 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート
AU2014250983B2 (en) 2013-04-10 2019-04-11 Syndevrx, Inc. MetAP2 inhibitors and methods of treating obesity
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
RU2743077C2 (ru) 2013-12-25 2021-02-15 Дайити Санкио Компани, Лимитед Конъюгат анти-trop2 антитело-лекарственное средство
CN105829346B (zh) 2014-01-31 2019-08-23 第一三共株式会社 抗her2抗体－药物偶联物
ES2859648T3 (es) 2014-04-10 2021-10-04 Daiichi Sankyo Co Ltd Conjugado anticuerpo-fármaco anti-HER3
WO2015155976A1 (ja) * 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
ES2938186T3 (es) 2015-06-29 2023-04-05 Daiichi Sankyo Co Ltd Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco
WO2017100553A1 (en) 2015-12-10 2017-06-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN108697807B (zh) 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
US20190330368A1 (en) 2016-10-07 2019-10-31 Daiichi Sankyo Company, Limited Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY MEDICINAL CONJUGATE
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CN117838881A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
WO2019044947A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
EP4257611A3 (en) 2018-05-18 2024-03-06 Glycotope GmbH Anti-muc1 antibody
AU2019366819A1 (en) 2018-10-26 2021-06-03 Syndevrx Inc. Biomarkers of MetAP2 inhibitors and applications thereof
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59220197A (ja) * 1983-05-30 1984-12-11 Snow Brand Milk Prod Co Ltd 新規な含窒素多糖体およびその製造方法
JP2604930B2 (ja) 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
CA2081025A1 (en) 1991-02-21 1992-08-22 Kazuhiro Inoue Carboxymethylmannoglucans and derivatives thereof
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
EP0640622B1 (en) 1993-02-26 2000-08-09 Drug Delivery System Institute, Ltd. Polysaccharide derivative and drug carrier
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
WO2000025825A1 (fr) 1998-10-30 2000-05-11 Daiichi Pharmaceutical Co., Ltd. Composes dds et procede de dosage de ces composes

Also Published As

Publication number Publication date
EP0916348A1 (en) 1999-05-19
NO985666D0 (no) 1998-12-04
CA2257245A1 (en) 1997-12-11
EP0916348B1 (en) 2004-08-18
NO985666L (no) 1999-02-04
ID18298A (id) 1998-03-26
DE69730332T2 (de) 2005-09-22
EA001550B1 (ru) 2001-04-23
JP4137183B2 (ja) 2008-08-20
US6838450B2 (en) 2005-01-04
EP0916348A4 (en) 2000-11-29
US20030171262A1 (en) 2003-09-11
AU723392B2 (en) 2000-08-24
WO1997046260A1 (en) 1997-12-11
PT916348E (pt) 2004-10-29
ES2229354T3 (es) 2005-04-16
AU2978797A (en) 1998-01-05
DK0916348T3 (da) 2004-12-06
ATE273715T1 (de) 2004-09-15
CN1227499A (zh) 1999-09-01
US6436912B1 (en) 2002-08-20
DE69730332D1 (de) 2004-09-23
KR20000016558A (ko) 2000-03-25
TW527183B (en) 2003-04-11

Similar Documents

Publication Publication Date Title
NO985666L (no) Medikamentkompleks
NO301829B1 (no) 2-pyridylmetylenpolyazamakrocyklo-fosfonsyrer, komplekser og farmasöytiske preparater basert på disse
ATE208181T1 (de) Stimulation von haarwachstum mit peptid-kupfer- komplexen
DE69531204D1 (de) Formulierungen fuer faktor ix
GEP20012413B (en) Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
AU6701890A (en) Process for the production of biologically active protein
RU94017851A (ru) Ингибиторы протеолитических ферментов на основе производных сахарина, фармацевтическая композиция для лечения дегеративных заболеваний
FI925787A (fi) Proteolytiska enzymers sackarinderivatinhibitorer
NO302474B1 (no) Sakarinderivater, farmasöytisk sammensetning og anvendelse derav
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
WO1992016205A3 (en) Novel derivatives of 2-carboxyndoles having pharmaceutical activity
DE69124705D1 (de) Hexapeptide als liganden des anaphylatoxin-rezeptors
RU92016453A (ru) Гидроксамовые кислоты и n-гидроксимочевины, способы их получения, фармацевтическая композиция и способ ингибирования липоксигеназы
DK0700898T3 (da) L-carnitinsalt og kosmetiske og farmaceutiske præparater indeholdende samme, til behandling af dermatoser.
HU912010D0 (en) Utilization of macroring amino-phosphonic acid complexes as transformation agents
MY131384A (en) Novel 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
IT8868117A0 (it) Solfonammidi di benzilidene canfora derivanti da amminoacidi e loro impiego in cosmesi particolarmente come filtri solari
DE69018275D1 (de) Peptide, deren Verwendung als Hemmer gegen Entwicklung von t-Lymphocyten und Wirksamkeit von Makrophagen und Verfahren zu deren Herstellung.
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
FI933507A (fi) Bisyklopolyatsamakrosyklofosfonihappoja, niiden komplekseja ja konjugaatteja käytettäväksi varjoaineina ja menetelmä niiden valmistamiseksi
ATE164882T1 (de) Verfahren zur herstellung von aktivierten killer- monozyten und verfahren zur überprüfung ihrer tumoriziden aktivität
ATE36957T1 (de) N,n-diethyl-5-methyl-2h,1-benzothiopyrano-(4,3, - cd)-indazol-2-ethanamine, diese enthaltende zubereitungen und ihre verwendung.
EP0232500A3 (de) Di- und Tripeptide mit N-terminalem Phosphinothricin, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
ATE78828T1 (de) Verfahren und zwischenverbindungen fuer n-(s-3alkyl-heptanoyl)-d-gamma-glutamyl-glycyl-dalanine.
ITMI922534A1 (it) Uso di acidi aril-, eteroaril- e alchiltartronici come agenti terapeutici

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU